Target attainment with continuous dosing of piperacillin/tazobactam in critical illness: a prospective observational study

Highlights • Continuous dosing of piperacillin in critical illness does not yield a high sustained target. • Large variability in concentrations is seen in continuous dosing of piperacillin. • Higher continuous dosing of piperacillin and therapeutic drug monitoring is needed.

Saved in:
Bibliographic Details
Published in:International journal of antimicrobial agents 2017-07, Vol.50 (1), p.68-73
Main Authors: Aardema, Heleen, Nannan Panday, Prashant, Wessels, Mireille, van Hateren, Kay, Dieperink, Willem, Kosterink, Jos G.W, Alffenaar, Jan-Willem, Zijlstra, Jan G
Format: Article
Language:English
Subjects:
Adult
Aged
Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - pharmacokinetics
beta-Lactamase Inhibitors - administration & dosage
beta-Lactamase Inhibitors - pharmacokinetics
Chromatography, Liquid
Continuous dosing
Critical care
Critical Illness
Female
Humans
Infectious Disease
Male
Middle Aged
Netherlands
Penicillanic Acid - administration & dosage
Penicillanic Acid - analogs & derivatives
Penicillanic Acid - pharmacokinetics
Piperacillin
Piperacillin - administration & dosage
Piperacillin - pharmacokinetics
Plasma - chemistry
Prospective Studies
Tandem Mass Spectrometry
Young Adult
β-Lactam
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Continuous dosing of piperacillin in critical illness does not yield a high sustained target. • Large variability in concentrations is seen in continuous dosing of piperacillin. • Higher continuous dosing of piperacillin and therapeutic drug monitoring is needed.
ISSN:0924-8579
1872-7913
DOI:10.1016/j.ijantimicag.2017.02.020